Rapid, low-cost, and accurate tests are still required for epidemiological surveillance and healthcare services to monitor and contain the spread of SARS-CoV-2. Brazilian researchers have contributed to this field's efforts by creating an electrochemical immunosensor that identifies antibodies against the virus.

The Drugs Controller General of India (DCGI) has given approval to intranasal "Five Arms" booster dose for restricted use for COVID-19 patients, it is learnt.

New Delhi [India], August 22 (ANI): A top scientist of the Indian Council of Medical Research-National Institute of Virology on Monday stated that the rising Monkeypox cases will not lead to human immunodeficiency virus (HIV).

New Delhi [India], June 24 (ANI/BusinessWire India): J Mitra & Co has been conferred the Healthcare Leadership Award 2022 for being the 'Pioneers of IVD Test Kits in India.' J Mitra & Company was given this Award at the 10th Healthcare Innovation Summit. The Award was accepted by Jatin Mahajan, Managing Director of the company today, at the glittering ceremony held in Delhi.

Hyderabad (Telangana) [India], December 30 (ANI): Hyderabad based vaccine manufacturer Bharat Biotech on Thursday announced that Covaxin (BBV152) has been found to be "safe, well-tolerated, and immunogenic" in the age group of 2-18 years in phase II/III study, said a company's statement.

Hyderabad Dec 30 PTI Bharat Biotech International Limited BBIL on Thursday announced that BBV152 Covaxin its whole-virion inactivated COVID-19 vaccine candidate has proven to be safe well-tolerated and immunogenic in paediatric subjects in phase IIIII study Bharat Biotech had conducted phase IIIII open-label and multicenter studies to evaluate the safety reactogenicity and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 age group a press release from the vaccine maker said Krishna Ella Chairman and Managing Director Bharat Biotech said Covaxins clinical trial data from the paediatric population is very encouraging Safety of the vaccine is critical for children and we are glad to share that Covaxin has now proven data for safety and immunogenicity in children We have now achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children The clinical trials conducted in the paediatric population between June-September 2021 have shown robust safety reactogenicity and immunogenicity The data was submitted to the Central Drugs Standard Control Organisation CDSCO during October 2021 and received emergency use nod for children aged 12-18 from DCGI recently In the study no serious adverse event was reported A total of 374 subjects reported either mild or moderate severity symptoms with 786 per cent getting resolved within a day Pain at the injection site was the most commonly reported adverse event the release said For the trial 976 subjects were screened for SARS-CoV-2 by RT-PCR and ELISA testing enzyme-linked immunoassay Out of these 525 eligible participants were enrolled Based on the age participants were distinguished into three groups in an age de-escalatory manner PTI GDK APR APR

pWith these cases the tally of confirmed dengue cases in the district has reached 193 this year Of these 120 62 have been reported in September alone The number does not include suspected cases many of which are being reported at private hospitalsp

Kanpur (Uttar Pradesh) [India], September 15 (ANI): Amidst the dengue outbreak in several districts of Uttar Pradesh, the Chief Medical Officer (CMO) of Kanpur Dr Ashok Shukla on Tuesday informed that there are 103 cases of dengue across the district.

Gorakhpur (Uttar Pradesh) [India], September 14 (ANI): The Gorakhpur district administration has made preparation to curb the spread of dengue in the district.

Firozabad/Agra/ Prayagraj/Gorakhpur (Uttar Pradesh) [India], September 14 (ANI): A surge in dengue cases has been seen among children in various districts of Uttar Pradesh.